

## Disclosures

### Personal Commercial (11)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Altavant	Research/Research Grants	None (\$0)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Arena	Other - Adjudication committee	Modest (< \$5,000)	<i>Vascular Medicine</i>
Gossamer Bio	Research/Research Grants	None (\$0)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Gossamer Bio	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Janssen	Research/Research Grants ‡ GRIPHON	Significant (>= \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Janssen	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Merck & Co., Inc.	Research/Research Grants	None (\$0)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Merck & Co., Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
Shouti	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
United Therapeutics	Research/Research Grants	None (\$0)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>
United therapeutics	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (2)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Circulation	Other - Associate Editor	Significant (>= \$5,000)	<i>General Cardiology</i>
UC San Diego ‡ Bayer Healthcare Pharmaceuticals through grant to UCSD	Other - Steering Committee, CTEPH Registry	Modest (< \$5,000)	<i>Pulmonary Hypertension and Venous Thromboembolic</i>

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 3/20/2022

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 3/20/2022

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

**Embargo** | Signed on 3/20/2022

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

**On-Going Obligation Agreement** | Signed on 3/5/2023

---

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.